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Summary: Non-enzymatic glycation of plasma proteins may contribute to the excess risk of developing
atherosclerosis in patients with diabetes mellitus. Glycated apolipoprotein A-I isolated from diabetic subjects
was tested in vitro for its ability to activate lecithin : cholesterol acyltransferase, the principal cholesterol-
esterifying enzyme in plasma. Activation by glycated apolipoprotein A-I was significantly lower at all
concentrations than the activation by normal apolipoprotein A-I. Linear regression analysis of the kinetic
data shows that the ratio app V^/app Km was significantly lower (p < 0.01) for glycated apolipoprotein Α-
Ι (0.29 nmol · 1/h · μιηοΐ) than for normal apolipoprotein A-I (0.78 nmol · 1/h · μιηοΐ). Because lecithin :
cholesterol acyltransferase provides a driving force in reverse cholesterol transport by esterifying the cellular
cholesterol removed by HDL, it is tempting to postulate that this abnormal'activation may be associated
with a reduction in reverse cholesterol transport and associated with the accelerated development of athero-
sclerosis in diabetic patients.
Introduction with high density lipoprotein (3) and a defective abil-
ity to activate lecithin: cholesterol acyltransferase (4).
Another variant, (Pro143 —-> Arg), in which proline-Apolipoprotein A-I is the major protein constituent A « /T> 143of human high density hpoprotems (HDL). The pro- 4 A~ . , ^ A ,, . . . . f. °- ' . . j ., ^ ' . 143 is substituted by argmine is a poorer activator oftern contains 243 ammo acid residues and its primary , . , . , _ , 1 1 r ι. · ι. , /<1N _, · · ι ι_ · ι · * lecithin : cholesterol acyltransferase than is normalstructure is known (1). The principal physiological ,. . A T /cxr · r ι· * · Λ τ F K J 6 apolipoprotein A-I (5).functions of apolipoprotein A-I are: ^ ^ "  ^
4 N . 4 . ., .. ., . ,, - r,. , , . Post-translational modifications of apolipoprotein1) interaction withlipids in the surf ace of high density A T . . . r . r , . ^ ,. ^.. A . ' , - . , 4 4 , - . A-I may also alter the function of this apolipoprotein.lipoprotein, thereby ensunng t h e structural cohesion W t . , J t Ι - - Λ Τr ΤΤ-ΓΝΤ *· ι j We have previously reported that apolipoprotem A-Iof HDL particles, and - v · , · · j- i. -undergoes a non-enzymatic glycation in diabetic sub-
2) activation of the enzyme lecithin : cholesterol acyl- jects (6) and that this modification alters its self-
transferase (2), which is responsible for the esterifi- association and lipid binding properties in vitro (7).
cation of cholesterol in human plasma. More recently, we have shown that the non-enzymatic
Several genetically determined variants of apolipo- g)ycation of apolipoprotein A-I diminishes its asso-
protein A-I have been described in the human pop- °iatl°n Wlth hlgh density hP°Protein in V1VO (8)·
ulation and the effects of these mutations on the In this report we document that glycated apolipopro-
apolipoprotein functions have been tested. The vari- tein A-I purified from the plasma of diabetic subjects
ant (Lysioy-o) in which lysine at residue 107 is deleted is deficient in its ability to activate lecithin: cholesterol
have been proved to have a decreased association acyltransferase in vitro.
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Materials and Methods
Purification of apolipoprotein A-I and glycated apo-
l ipoprotein A-I
High density lipoprotein was isolated from pooled fresh non-
diabetic and diabetic human plasma by sequential ultracentri-
fugation in the density range 1.063-1.20 kg/1 (9). HDL was
delimitated with ether: ethanol (3 + 1 by vol.) at 4 °C and the
apolipoproteins were fractionated on a Sephadex G 150 column
(10). Giycated apolipoprotein A-I was purified from the apo-
lipoprotein A-I of diabetic patients by affinity chromatography
in aminophenylboronic acid (Affi Gel 601) (7). All apolipopro-
tein preparations yielded a single band on SDS-polyacrylamide
electrophoresis. Absence of other posttranslational modifica-
tions of apolipoprotein A-I and glycated apolipoprotein A-I
was confirmed by amino acid analysis. Glycated apolipoprotein
A-I contains 1—2 glucose molecules per apolipoprotein A-I
molecule.
Purification of lecithin : cholesterol acyltransferase
Lecithin : 9holesterol acyltransferase was prepared as described
previously (11). Briefly, fresh human plasma was ultracentri-
fuged at d = 1.23 kg/1 for 48 h at 45000 min"1 in a Ti 50 rotor
at 10 °C. The clear middle zone between the floating lipopro-
teins and the sedimenting plasma proteins was aspirated, dia-
lysed and chromatographed on a column containing DEAE
cellulose. Fractions containing lecithin : cholesterol acyltrans-
ferase activity were precipitated with ammonium sulphate and
butanol and chromatographed on a Sephadex G 100 column.
The purity of this enzyme fraction was assessed by polyacryl-
amide gel electrophoresis in 10 g/1 sodium dodecyl sulphate.
Substrates
Micellar, discoidal substrates containing 2843 μιηοΐ/ΐ of 1-pal-
mitoyl-2-oleoyl-iw-glycero 3-phosphorylcholine, 125 μπιοΐ/ΐ of
free cholesterol, 42 MBq/1 of [3H]cholesterol and various (3.5,
7.0, 14.0, 21.0, 28.9, and 35.0) μπιοΐ/ΐ of apolipoprotein A-I or
glycated apolipoprotein A-I, were prepared by the sodium
cholate dialysis method (12).



































Assay of the lecithin : cholesterol acyltransferase-
activating property of apolipoprotein A-I and gly-
cated apolipoprotein A-I
Eighty μΐ of substrate, 20 μΐ of 2-mercaptoethanol, ΙΟμΙ of
human serum albumin (50 g/1) and 140 μΐ of Tris-HCl 10
mmol/1, pH 7.4 were preincubated in a shaking water bath at
37 °C for 60 min. The reaction was initiated by addition of
50 μΐ of lecithin : cholesterol acyltransferase (0.30 g/1) and
continued for 30 min under the same conditions. The reaction
was stopped by the addition of 0.5 ml of methanol. The meth-
anol-containing incubation mixture was extrated with 1 ml of
hexane. Cholesteryl esters were separated from free cholesterol
by silica gel column chromatography (elution with diethyl ether
: hexane (1 + 6, by vol.).
The labelled cholesteryl esters were cqllected, mixed with 5 nil
of scintillation cocktail and the radioactivity was measured in
a liquid scintillation analyser, Packard 1600 TR. Blanks without
enzyme were run in parallel. All the experiments were performed
in duplicate. The precision of the method was 9.6%, as ex-
pressed by the coefficient of variation.
The activity of lecithin : cholesterol acyltransferase was calcu-
lated from the specific radioactivity of cholesterol and expressed
as nmol of cholesterol ester formed per hour. Linear regression
analysis was used to obtain the apparent (app) kinetic constants:
app. Vmax, app. Km> and app. Vmax/app. Km.
Results
Apolipoprotein A^I and glycated apolipoprotein A-I
were individually tested for their ability to activate
lecithin : cholesterol acyltransferase in vitro.
Concentration-dependent, saturable activation of the
enzyme reaction was observed for both the apolipo-
protein A-I and the glycated apolipoprotein A-I. The
results of the activator saturation experiments were
analysed by the double reciprocal plot ace. to Linew-
eaver-Burk using normal Michaelis-Menten kinetics.
As shown in figure 1, the activation of esterification
by glycated apolipoprotein A-I was significantly lower





Fig. 1. Lineweaver Burk plots giving the reciprocal initial ve-
locity of cholesterol esterification (l/v0) as a function of
the reciprocal substrate concentration, apolipoprotein
A-I (o) and giycated apolipoprotein A-I (·) (1/[SJ).
Lecithin : cholesterol acyltransferase activity was as-
sayed at 37 °C by measuring the formation of
[3H]cholesterol esters from different liposomes, contain-
ing various amounts of apolipoprotein A-I or glycated
apolipoprotein A-I. The reaction was initiated by ad-
dition of 50 μΐ of lecithin : cholesterol acyltransferase
and stopped after 30 min by adding 0.5 ml of methanol.
Regression equations:
Apolipoprotein A-I:
- = (3.462 ± 0:524) -^ + Ό.320v LSI ,;
Glycated apolipoprotein A-I:
- = (1.279 ± 0.019) -i- + 0.241
v [S]
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Tab. J . Apparent kinetic constants for the micellar complexes
Apolipoprotein A-I (n =
Glycated apolipoprotein
12)



















From linear regression analysis of kinetic data as shown in figure 1 app. Vmax is the reciprocal of the y-intercept; app.
Vmax is the slope of the line; and app. Km is calculated from the other two quantities. The ratio app. Vmax/app. Km was significantly
lower for glycated apolipoprotein (p < 0.01) using the Student's t-statistical test.
Table 1 gives the results from the linear regression
analysis of the kinetic data: correlation coefficients,
apparent Vmax, apparent Km and app. Vmax/app. Km
quantities. The app. Vmax/app. Km of glycated apoli-
poprotein A-I differs significantly from that of normal
apolipoprotein A-I (p < 0.01).
Discussion
The present study indicates that glycated apolipopro-
tein A-I isolated from diabetic subjects is deficient in
activating lecithin : cholesterol acyltransferase in vi-
tro.
Information is very limited on the lecithin : cholesterol
acyltransferase activity in the plasma of patients with
diabetes mellitus. Fielding and coworkers (13) de-
scribed decreased activity of lecithin : cholesterol acyl-
transferase in diabetics, whereas Schernthaner et al.
(14) found normal activity. Gugliucci et al. (15) re-
ported that 10 — 15% glycation of lysine residues in
apolipoprotein A-I produces a 40% decrease in leci-
thin : cholesterol acyltransferase activation, compared
with the control. In the present study, differences in
the reactivity of lecithin : cholesterol acyltransferase
with glycated apolipoprotein A-I become measurable
when the degree of glycation of lysine residues reached
3-5%.
An important consideration in studies of lecithin :
cholesterol acyltransferase activity is the use of ap-
propriate kinetic parameters to compare the reactiv-
ities of different substrates. In this report the ratio,
apparent Vmax/apparent Km, was used to monitor the
response of the enzyme to different substrates, after
interaction of the enzyme with various concentrations
of apolipoprotein A-I.
Studies using a series of native and synthetic frag-
ments of apolipoprotein A-I support the concept that
the interaction of the protein with lipids is of prime
importance for this activating capacity of apolipopro-
tein A-I (11, 16, 17). Lecithin : cholesterol acyltrans-
ferase does not require apolipoprotein to bind to lipid
interfaces; however, on a pure lipid surface the active
site may not be accessible to the lipid substrates (18).
When apolipoprotein is present, the access of sub-
strates to the active site may be facilitated by a direct
interaction of the enzyme with the protein cofactor,
or by an activation of the lipid substrates via the
protein cofactor. It is possible that the glycation of
lysine may cause a disruption in the relationships^
some portions of the apolipoprotein A-I structure.
Studies of lecithin : cholesterol acyltransferase acti-
vation by synthetic peptides have led to the proposal
that the major lecithin : cholesterol acyltransferase-
activating domain of apolipoprotein A-I resides in the
22mer tandem repeats, located between residues 66
and 121 of the native apolipoprotein (19). Therefore,
additional studies will be required in order to identify
the preferential site of non-enzymatic glycation in
apolipoprotein A-I, and to establish whether this in-
volves amino acid residues that are specifically re-
quired in lecithin : cholesterol acyltransferase activa-
tion.
The significance in vivo of this decreased lecithin :
cholesterol acyltransferase activation by glycated apo-
lipoprotein A-I remains to be established. Because
lecithin: cholesterol acyltransferase provides a driving
force in reverse cholesterol transport by esterifying
the cellular cholesterol removed by high density lipo-
proteins, it is possible that this abnormal activation
may be associated with a reduction in reverse choles-~
terol transport and with the accelerated development
of atherosclerosis in patients with diabetes mellitus.
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